On the 18th, D&D Pharmatech closed firm as bargain hunting flowed in despite market uncertainty caused by the U.S. Federal Reserve's decision to hold its benchmark interest rate steady.

According to the Korea Exchange, D&D Pharmatech finished the day at 108,300 won, up 200 won (0.19%) from the previous trading day. The stock opened at 107,800 won and showed a downward trend during the session, dipping as low as 104,000 won, before recovering its losses and climbing to 111,800 won. Although it gave up some of its gains by the close, it successfully managed to turn upward. Trading volume for the day reached 1,791,601 shares, with a transaction value of approximately 193.8 billion won.

The market views that investor sentiment was constrained because, even though the Fed froze interest rates, it did not completely rule out uncertainty over the future direction of monetary policy and the possibility of additional tightening. Accordingly, analysts note that a wait-and-see approach persisted, centered on growth and biotech stocks.

Nevertheless, D&D Pharmatech continued to receive steady attention from investors, driven by ongoing expectations regarding its new drug development pipeline and clinical trial progress. It is interpreted that despite expanded intraday volatility, bargain hunting flowed in to defend against a stock price decline.

Securities firms project that future changes in the global interest rate environment, key clinical schedules, and the possibility of technology transfers will act as key variables determining D&D Pharmatech's stock price trajectory.

[This article was partially produced with the aid of AI. This article was written with the help of AI based on market analysis data and publicly available information, and is not intended to solicit investment. The responsibility for investment lies with the investor.]